Summary & Overview
HCPCS J0219: Injection, avalglucosidase alfa-ngpt, 4 mg
HCPCS Level II code J0219 designates a 4 mg dose of avalglucosidase alfa-ngpt administered by injection, typically used as an enzyme replacement therapy. Nationally, this code matters for accurate reporting of specialty biologic administration, billing for infusion services, and tracking utilization of high-cost therapies. It is relevant to hospitals, outpatient infusion centers, and specialty clinics that provide enzyme replacement treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this HCPCS Level II code is used in clinical and billing workflows, benchmarks for service lines that commonly bill for infusion therapies, and the clinical context for avalglucosidase alfa-ngpt administration. The publication also summarizes typical sites of service and common billing considerations for therapeutic injections.
The content that follows provides benchmarks where available, notes on coverage patterns for the listed payers, and an explanation of the clinical indication and service delivery settings associated with J0219. Data not provided in the input are noted as unavailable.
Billing Code Overview
HCPCS Level II code J0219 represents an injection of avalglucosidase alfa-ngpt, 4 mg. This code is used to report administration of the specified enzyme replacement therapy formulation and strength.
Service Type: Therapeutic injection / infusion
Typical Site of Service: Infusion center, outpatient hospital, or clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual diagnosed with Pompe disease (glycogen storage disease type II) who requires enzyme replacement therapy with avalglucosidase alfa-ngpt. The infusion is administered in an outpatient infusion center, hospital outpatient department, or skilled nursing facility by an infusion nurse under the supervision of a metabolic or neuromuscular specialist. Prior to each administration, the patient undergoes clinical assessment including vital signs, review of prior infusion reactions, and verification of premedication orders (antihistamines, corticosteroids) if indicated. The medication J0219 is prepared by pharmacy in appropriate dosing vials and delivered via intravenous infusion over a monitored period; monitoring includes observation for infusion-associated reactions, documentation of dose and lot numbers, and post-infusion assessment. Patient-specific considerations include infusion site access (peripheral IV vs. central line), weight-based dosing adjustments, and documentation of any modifier that reflects unusual circumstances (e.g., split billing, discarded drug). Follow-up appointments with the metabolic specialist are scheduled to assess treatment response, respiratory and cardiac function, and to plan ongoing infusions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard use when no modifier applies |